Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prev close 4.87 · gapped above the open, then crossed back over prior close. High/low 5.00 at 9:45 am ET, 4.86 at 3:30 pm ET.
Cytek Biosciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Laboratory Analytical Instruments
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“Pursuant to the Coherent Agreement, Coherent has agreed to sell and supply to us, Cytek Wuxi, and Cytek Singapore, on a non-exclusive basis, laser products manufactured by Coherent.”
FILING10-K0001628280-26-012352cik 0001831915
“On September 1, 2020, we entered into a Supply and License Agreement with Biotium, Inc. ("Biotium") pursuant to which Biotium agreed to supply, and we obtained a worldwide, non-exclusive license to market and resell to our customers and distributors, certain Biotium products to conjugate proteins and/or antibodies and to use such conjugates as a component in our cFluor reagent products, for research and analyte specific reagents (as defined by 21 CFR 864.4020) use only (the "Field of Use") (the "Biotium Agreement").”
FILING10-K0001628280-26-012352cik 0001831915
“For example, in February 2023, we entered into an asset purchase agreement with Luminex Corporation ("Luminex") and acquired certain assets related to the flow cytometry and imaging business unit of Luminex (the "FCI Acquisition").”
FILING10-K0001628280-26-012352cik 0001831915
“As part of the settlement, BD granted us a non-exclusive, irrevocable, perpetual, worldwide, and non-transferrable license to certain BD patents and covenanted that it would not enforce, or permit or encourage the enforcement of BD patents against us or our affiliates in connection with the development, manufacture, use, importation, offer for sale or sale of our then-current instruments.”
FILING10-K0001628280-26-012352cik 0001831915
“Net cash used in investing activities during the year ended December 31, 2024 was $83.0 million driven by purchases of marketable securities of $274.1 million, purchases of property and equipment of $3.5 million, the purchase of the Cytometric Engineering Ltd. (d.b.a. FlowCEL) business of $0.5 million, and purchase of intangible assets of $0.2 million, partially offset by proceeds from maturities of marketable securities of $195 million, and proceeds from sales of property and equipment of $0.3 million.”
FILING10-K0001628280-26-012352cik 0001831915
Watchlist prices, news filtered to it, and its next report on your desk.
Cytek Biosciences, Inc. has 5 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Cytek Biosciences, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Cytek Biosciences, Inc.. Customers appear here when Cytek Biosciences, Inc. names them, or when a company names Cytek Biosciences, Inc. as a supplier in its own annual report.
CTKB (Cytek Biosciences, Inc.) has 5 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: BDX +1.56%, in healthcare.